Medische Oncologie Nummer 4, pp. 13-15
sep 2007, jaargang 10
Medische Oncologie Nr. 4, pp. 13-15
sep 2007, jr. 10
Wetenschap

De plaats van CYP2D6-genotypering bij tamoxifenbehandeling van mammacarcinoom

Het ASCO-jaarcongres in juni 2007 presenteerde opvallend nieuws over een – vermoedelijke – rol van het CYP2D6-genotype bij de behandeling van mammacarcinoom met tamoxifen. De belangrijkste vraag voor de clinicus is of het CYP2D6-genotype, en daarmee het voorspelde fenotype, daadwerkelijk is gerelateerd aan een klinische uitkomst. In hoeverre kunnen tot op heden gepubliceerde studieresultaten uitsluitsel hierover geven?

Referenties

  1. The value of estrogen and progesterone receptors in the treatment of breast cancer. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL.Cancer 1980;46:2884-8.
  2. Tamoxifen in the treatment of breast cancer. Osborne CK.N Engl J Med 1998;339(22):1609-18.
  3. Use of tamoxifen for breast cancer: twenty-eight years later. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN.J Clin Oncol1995;13(2):513-29.
  4. Endocrine therapy in the treatment of metastatic breast cancer. Buzdar AU. Semin Oncol 2001;28(3):291-304.
  5. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Stearns V, Johnson MD, Rae JM, et al.J Natl Cancer Inst2003;95(23):1758-64.
  6. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Johnson MD, Zuo H, Lee KH, et al. Breast Cancer Res Treat 2004;85(2):151-9.
  7. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Jin Y, Desta Z, Stearns V, et al.J Natl Cancer Inst 2005;97(1):30-9.
  8. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Zanger UM, Raimundo S, Eichelbaum M. Naunyn Schmiedebergs Arch Pharmacol2004;369(1):23-37.
  9. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Bradford LD.Pharmacogenomics2002;3:229-43. 
  10. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Borges S, Desta Z, Li L, et al.Clin Pharmacol Ther 2006;80(1):61-74.
  11. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Goetz MP, Rae JM, Suman VJ, et al. J Clin Oncol 2005;23(36):9312-8.
  12. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Goetz MP, Knox SK, Suman VJ, et al.Breast Cancer Res Treat 2007;101(1):113-21.
  13. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. Bonanni B, Macis D, Maisonneuve P, et al.J Clin Oncol 2006;24(22):3708-9. 
  14. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Nowell SA, Ahn J, Rae JM, et al.Breast Cancer Res Treat2005;91(3):249-58. 
  15. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Wegman P, Vainikka L, Stål O, et al.Breast Cancer Res2005;7(3):R284-90.
  16. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Wegman P, Elingarami S, Carstensen J, et al.Breast Cancer Res2007;9(1):R7
  17. FDA summary minutes of meeting of the Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science.October 18-19, 2006.
Wetenschap

De plaats van CYP2D6-genotypering bij tamoxifenbehandeling van mammacarcinoom

Het ASCO-jaarcongres in juni 2007 presenteerde opvallend nieuws over een – vermoedelijke – rol van het CYP2D6-genotype bij de behandeling van mammacarcinoom met tamoxifen. De belangrijkste vraag voor de clinicus is of het CYP2D6-genotype, en daarmee het voorspelde fenotype, daadwerkelijk is gerelateerd aan een klinische uitkomst. In hoeverre kunnen tot op heden gepubliceerde studieresultaten uitsluitsel hierover geven?

Referenties

  1. The value of estrogen and progesterone receptors in the treatment of breast cancer. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL.Cancer 1980;46:2884-8.
  2. Tamoxifen in the treatment of breast cancer. Osborne CK.N Engl J Med 1998;339(22):1609-18.
  3. Use of tamoxifen for breast cancer: twenty-eight years later. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN.J Clin Oncol1995;13(2):513-29.
  4. Endocrine therapy in the treatment of metastatic breast cancer. Buzdar AU. Semin Oncol 2001;28(3):291-304.
  5. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Stearns V, Johnson MD, Rae JM, et al.J Natl Cancer Inst2003;95(23):1758-64.
  6. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Johnson MD, Zuo H, Lee KH, et al. Breast Cancer Res Treat 2004;85(2):151-9.
  7. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Jin Y, Desta Z, Stearns V, et al.J Natl Cancer Inst 2005;97(1):30-9.
  8. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Zanger UM, Raimundo S, Eichelbaum M. Naunyn Schmiedebergs Arch Pharmacol2004;369(1):23-37.
  9. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Bradford LD.Pharmacogenomics2002;3:229-43. 
  10. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Borges S, Desta Z, Li L, et al.Clin Pharmacol Ther 2006;80(1):61-74.
  11. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Goetz MP, Rae JM, Suman VJ, et al. J Clin Oncol 2005;23(36):9312-8.
  12. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Goetz MP, Knox SK, Suman VJ, et al.Breast Cancer Res Treat 2007;101(1):113-21.
  13. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. Bonanni B, Macis D, Maisonneuve P, et al.J Clin Oncol 2006;24(22):3708-9. 
  14. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Nowell SA, Ahn J, Rae JM, et al.Breast Cancer Res Treat2005;91(3):249-58. 
  15. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Wegman P, Vainikka L, Stål O, et al.Breast Cancer Res2005;7(3):R284-90.
  16. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Wegman P, Elingarami S, Carstensen J, et al.Breast Cancer Res2007;9(1):R7
  17. FDA summary minutes of meeting of the Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science.October 18-19, 2006.
Over dit artikel
Auteurs
Vincent Dezentjé, Henk-Jan Guchelaar, Hans Nortier, Hans Gelderblom
Over de auteurs

Vincent Dezentjé, arts-onderzoeker, Henk-Jan Guchelaar, ziekenhuisapotheker en klinisch farmacoloog ,Hans Nortier, internist-oncoloog, Hans Gelderblom, internist-oncoloog

Printdatum
14 september 2007
E-pubdatum
17 september 2007
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteurs
Vincent Dezentjé, Henk-Jan Guchelaar, Hans Nortier, Hans Gelderblom
Over de auteurs

Vincent Dezentjé, arts-onderzoeker, Henk-Jan Guchelaar, ziekenhuisapotheker en klinisch farmacoloog ,Hans Nortier, internist-oncoloog, Hans Gelderblom, internist-oncoloog

Printdatum
14 september 2007
E-pubdatum
17 september 2007
ISSN print
1388-2295
ISSN online
2405-4763